

Sleep Duration and the Risk of Metabolic Syndrome: a Systematic Review and Meta-analysis

1 Jianian Hua^{13,#}, Hezi Jiang^{23,#}, Qi Fang^{1,*}

2 ¹ Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215006,
3 Jiangsu Province, China.

4 ² Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

5 ³ Medical College of Soochow University, Suzhou 215123, PR China.

6 [#]These authors contributed equally.

7 ^{*}Corresponding author

8 Qi Fang

9 fangqi_008@126.com

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 **Abstract**

35 Objective: Epidemiologic studies have reported inconsistent findings about the association between
36 sleep duration and metabolic syndrome. We aimed to clarify this association by method of meta-
37 analysis.

38 Methods: Medline, Embase, CINAHL and PsycINFO databases were searched from inception to
39 May 2020. We collected data from 235,895 participants from 9 prospective cohort studies, and
40 340,492 participants from 26 cross-sectional studies. Risk ratios (RR) or odds ratios (OR) were
41 calculated separately for cohort studies and cross-sectional studies, through meta-analysis of adjusted
42 data from individual studies.

43 Results: For cohort studies, short sleep duration was associated with an increased risk of metabolic
44 syndrome (RR, 1.15; 95% CI, 1.05-1.25). Long sleep duration was not associated with new onset
45 metabolic syndrome (RR, 1.02, 0.85-1.18). For cross-sectional studies, both short (OR, 1.12, 95% CI,
46 1.08-1.18) and long (OR, 1.06, 1.01-1.11) sleep duration was associated with high prevalence of
47 metabolic syndrome.

48 Conclusions: Only short sleep duration was associated with an increased risk of metabolic syndrome.
49 Future studies should address whether the association is casual and modifiable.

50 **Keywords:** sleep duration, metabolic syndrome, cohort study, meta-regression, meta-analysis

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **1 Introduction**

72 Metabolic syndrome is a cluster of disorders that occur together, and it is defined as a condition
73 consisting of at least three of the following: hypertension, high blood sugar, excessive waist
74 circumference, higher triglyceride (TG) levels or low high-density cholesterol (HDL) levels.
75 Metabolic syndrome is associated with adverse cardiovascular events, even after adjusted for diabetes
76 and obesity^{1,2}. Meanwhile, the prevalence of metabolic syndrome in America is up to 33%³. Recently,
77 growing concern has been paid to the modifiable risk factors of metabolic syndrome⁴.

78 Abnormal sleep duration is known to increase the risk of a serious health outcomes, including
79 mortality, diabetes and cardiovascular disease^{5,6}. Therefore, both sleep and metabolic syndrome
80 increase the risk of cardiovascular event. However, whether abnormal sleep duration increase the risk
81 of metabolic syndrome remained controversial. Several meta-analyses have reported the association
82 between sleep duration and metabolic syndrome⁷⁻⁹. However, none of the studies assessed the
83 association in a prospective cohort design, which has less substantial bias could provide stronger
84 support for causality^{6,10,11}.

85 Therefore, we conducted a systemic review and meta-analysis to: (1) examine all prospective cohort
86 studies that have assessed the effect of sleep duration on the future risk of metabolic syndrome; (2)
87 conduct an updated meta-analysis to examine the cross-sectional association.

88 **2 Materials and Methods**

89 We performed this study according to Preferred Reporting Items for Systematic Reviews and Meta-
90 Analysis (PRISMA) guidelines (Table S1).

91 Two independent researchers (JNH and HZJ) separately assessed the eligibility, extracted data, and
92 checked the quality of the included studies. Any disagreement in screening the articles were resolved
93 through discussion between these two, with adjudication by a third research (QF) if disagreements
94 persisted.

95 **2.1 Search strategy**

96 A systematic search was conducted in Medline, Embase, CINAHL and PsycINFO from inception to
97 May 2020. We used the following search terms: (1) "sleep hour" OR "sleeping hour" OR "hours of
98 sleep" OR "sleep duration" OR "sleep time" OR "sleep length" OR "sleep period" OR "sleeping time"
99 OR "sleep span"; (2) "metabolic syndrome" or "MetS" or "MS" or "syndrome X" or "cardiometabolic
100 risk factor" or "insulin resistance syndrome". Algorithms combining the two sets of search terms
101 were applied.

102 **2.2 Study selection**

103 Studies that examined the relationship between sleep duration and metabolic syndrome were
104 screened for eligibility, without language restriction. The inclusion criteria were: (1) the research was
105 a cohort or a cross-sectional study; (2) the research compared individuals with “unnormal” and
106 “normal” sleep duration on the outcome of metabolic syndrome. If one or more articles reported data
107 from one study, the article with the largest sample size and the best design was included.

108 We analyzed cohort studies and cross-sectional studies separately in all analysis due to the following
109 reasons. First, cross-sectional study could not establish a causal relationship, and it only reflected the
110 association between sleep duration and the prevalence of metabolic syndrome¹¹. Second, the non-
111 exposed prevalence of metabolic syndrome was higher than 20%¹², odds ratios (OR) could not be
112 regarded as risk ratio (RR)¹³.

113 The inclusion of studies was conducted in two stages: (1) screening of the title and abstract and (2)
114 screening of the full text.

115 **2.3 Data extraction**

116 The following characteristics were extracted from each eligible study: author name and publication
117 year, study type, study location (country and continent), sample size, participants’ characteristics (age
118 range, mean age and sex composition), exposure and outcome assessment (sleep assessment,
119 metabolic syndrome measures and definition of long or short sleep duration) and main results.

120 Since definition of sleep duration varies among studies¹⁴, the three categories of sleep duration (short,
121 long and normal) was extracted by one of the following two ways. For some papers, sleep duration
122 was already divided into three categories based on cultures and ethnicities. For others, in which sleep
123 duration was divided into more than three groups, short or long sleep duration was defined as the
124 shortest or longest group reported in the article⁶. With regard to the main results, the adjusted
125 estimates that reflected the most comprehensive control were extracted.

126 Data were extracted by two investigators (JNH and HZJ) independently. Disagreement in screening
127 the articles was resolved by discussion between the two investigators. Consultation from a third
128 investigator (QF) was acquired if necessary.

129 **2.4 Exposure and outcome measures**

130 With regard to the measurements of nocturnal sleep duration, two studies used objective
131 measurement, while others used interview or questionnaire.

132 The diagnostic criteria of metabolic syndrome (MetS) varied between studies. 10 studies used the
133 Third Report of the National Cholesterol Education Program’s Adult Treatment Panel III (NECP
134 ATP-III); 4 studies used modified NECP ATP-III; 14 studies used the American Heart
135 Association/National Heart Lung and Blood Institute (AHA-NHLBI); 3 studies used the International
136 Diabetes Federation (IDF)⁸; 5 studies used other criteria.

137

138 **2.5 Quality appraisal**

139 The quality of all studies was evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS)¹⁵.
140 The total score ranged from 0-9 scores. For outcome category and comparability category, all the
141 studies had similar quality. The difference between studies lied in the study design category (Table
142 S3).

143 **2.6 Data analysis**

144 We conducted all the following analysis separately for cohort studies and cross-sectional studies, and
145 for study-specific short and long sleep duration, respectively.

146 In analysis of cohort studies, hazard ratios (HRs) were regarded as risk ratios (RRs). For studies
147 which provided only odds ratios (ORs), we calculated RRs by using the ORs and control event rates
148 (CERs) in normal sleepers. Using random-effect models, we estimated the pooled RR and 95% CI.
149 With regard to cross-sectional studies, we calculated the pooled OR and 95%CI using random-effect
150 models.

151 Heterogeneity between the studies was assessed using Cochran Q statistics ($P < 0.1$ indicates
152 statistically significant heterogeneity) and I^2 statistic ($I^2 > 50\%$ indicates statistically significant
153 heterogeneity)¹⁶. To examine publication bias, we used a funnel plot, the Egger regression test, and
154 the Begg and Mazumdar test^{17,18}. “Trim and fill” method was used to adjust the funnel plot, and
155 recalculated the results^{19,20}. Sensitivity analysis was performed by excluding one study at a time to
156 test the robustness of the pooled estimates.

157 Subgroup analysis was conducted to explore the potential heterogeneity among cross-sectional
158 studies. We used z test to compare summary estimates of each subgroups²¹. Univariate and
159 multivariate meta-regression were used to study the effect of possible influential confounders, such
160 as definition of sleep duration and study quality. For cohort studies, subgroup analysis and meta-
161 regression was not performed considering the small number of datasets included in the meta-analysis.
162 All statistical analysis was performed by R-3.4.3²⁰ and Stata 15.1 (Stata Corp, College Station, TX).

163 **3 Results**

164 **3.1 Search results**

165 The initial electronic search yielded 1140 articles, among which 789 were reviewed by title and
166 abstract. 127 full-texts were retrieved. 35 studies were included in the final analysis (Figure 1).

167 **3.2 Characteristics of study samples**

168 We identified nine prospective cohort studies that examined the association between sleep duration
169 and the incident risk of metabolic syndrome, in a total of 235,895 participants. The sample size
170 ranged from 293 to 162,121. The mean follow-up duration ranged from 2 to 8 years (Table 1).

171 Another twenty-six studies were cross-sectional studies, included a total of 340,492 individuals. The
172 sample size ranged from 263 to 88,678 (Table S2).
173 Table 1 and Table S2 presented the characteristics of the all 35 studies. The individuals all aged
174 above 18 year. The mean (SD) age of the individuals ranged from 31 (8.7) to 67.6 (7.3) years. The
175 studies were conducted in five continents, while many of them were from Asia. The definitions of
176 short or long sleep duration varied between studies. About 75% studies defined “short sleep duration”
177 as < 6 or < 7 h, and about 80% studies defined “long sleep duration” as > 8 or > 9 h.

178 **3.3 Primary analysis**

179 **3.3.1 Sleep duration and the risk of metabolic syndrome**

180 Compared with moderate sleep duration, short sleep duration was associated with a statistically
181 significant increase in new onset metabolic syndrome, with an RR of 1.15 (95% CI=1.05-1.25,
182 $P<0.001$, $I^2=63.6\%$, N of datasets=11; Figure 2A).

183 Compared with moderate sleep duration, the association between long sleep duration and risk of
184 metabolic syndrome was not statistically significant, with an RR of 1.02 (95% CI=0.85-1.18,
185 $P=0.491$, $I^2=38.0\%$, N=9; Figure 2B), using random effect model. The RR reduced to 0.94 (95%
186 CI=0.89-0.99, $P=0.050$, $I^2=38.0\%$, N=9), using fixed effect model.

187 Among the seven studies that examined the effect of long sleep duration, six did not observe a
188 significant association. Only Li X. found that long sleep duration increased the risk of metabolic
189 syndrome among men (adjusted HR=1.96, 95% CI=1.35-2.85).

190 **3.3.2 Sleep duration and the prevalence of metabolic syndrome**

191 Compared with moderate sleepers, people with short or long sleep duration had a higher prevalence
192 of metabolic syndrome. The pooled OR of metabolic syndrome in short sleepers compared to
193 moderate sleepers was 1.06 (95% CI=1.01-1.11, $P<0.001$, $I^2=66.5\%$, N=32; Figure 3A). The pooled
194 OR of metabolic syndrome in long sleepers compared to moderate sleepers was 1.11 (95% CI=1.04-
195 1.17, $P<0.001$, $I^2=73.8\%$, N=31; Figure 3B).

196 **3.4 Possible publication bias for primary analysis**

197 Results of Begg and Mazumdar and Egger test were shown in Table S4. No significant publication
198 bias was observed. “Trim and fill” test indicated that the primary results was still significant after the
199 missing studies were filled in (Table S5). Visual inspection of the funnel plots also did not reveal
200 apparent publication bias (Figures not shown).

201 **3.5 Subgroup analysis**

202 Subgroup analysis of the cross-sectional studies were shown in Table 2. No significant subgroup
203 difference was found for gender, continent, and definition of abnormal sleep duration. There were
204 statistically significant subgroup effects ($P < 0.05$ for heterogeneity between groups). For short
205 sleepers, the specific domains were study population, sleep measurement, measures of metabolic
206 syndrome and sample size. For long sleepers, the specific domains were sleep measurement, long
207 sleep duration, measures of metabolic syndrome, sample size, and study quality. However, there was
208 still unexplained heterogeneity within some subgroups. Therefore, the subgroup couldn't fully
209 explain the overall heterogeneity.

210 For short sleepers, hospital-based participants had a higher OR than the community-based. With
211 regard to definition of short sleep duration, there was a tendency that lower duration was associated
212 with higher OR. Nevertheless, the P value was not significant.

213 For long sleepers, compared with "NECP" group, "modified-NECP" group had higher OR. Studies
214 with more participants or higher quality had lower OR.

215 **3.6 Sensitivity analysis**

216 None of the sensitivity analysis substantially altered the effect of both long and short sleep duration
217 on metabolic syndrome (Figure S1).

218 **3.7 Meta-regression**

219 With regard to cross-sectional studies, a multivariate meta-regression analysis (Table 3) was
220 conducted to examine the potential influence of different factors on the natural logarithm of the OR
221 of short or long sleep duration with prevalence of MetS. For short sleepers, shorter definition of
222 duration was associated with higher OR ($P = 0.011$ for multivariable test, and $P = 0.099$ for univariable
223 test). Higher study quality was associated with lower OR ($P = 0.010$ for univariable test and $P = 0.033$
224 for multivariable test). The effect of mean age was significant. However, the clinical effect (coef=
225 0.01) was little. For long sleepers, none of the study factors was significant.

226 **4 Discussion**

227 To our knowledge, this was the first meta-analysis on the association between sleep duration and the
228 risk of metabolic syndrome. Our study indicated that short sleep duration correlated with an increase
229 in the risk of metabolic syndrome. Long duration was not statistically associated with the risk of
230 metabolic syndrome. With regard to cross-sectional studies, both short and long sleep duration was
231 associated with higher prevalence of metabolic syndrome.

232 Our results differed from that of three previous meta-analysis, which reported the association
233 between sleep duration and metabolic syndrome. Limited by sample size, the three studies did not
234 distinguish cross-sectional studies and cohort studies in the main outcome. *Ju 2013* and *Iftikhar 2015*
235 reported only short sleep duration was associated with metabolic syndrome^{7,8}, while *Xi 2014* linked

236 both short and long sleep duration to metabolic syndrome⁹. Moreover, we observed narrower
237 confidence intervals, which might be due to our higher number of included datasets. Nowadays, a
238 growing number of articles reported an inverted-U shaped association between sleep duration and
239 health outcomes, including metabolic syndrome²². Our findings suggested that long sleep duration
240 might have no effect.

241 Compared with the previous studies, we further conducted comprehensive sub-group analysis and
242 meta-regression for cross-sectional studies. In subgroup analysis, using z test, we found no
243 statistically significant differences in subgroups of sex, continent, and sleep measurement. For short
244 sleepers, hospital-based participants had a higher prevalence than community-based participants,
245 which was consistent with a previous meta-analysis. One possible reason was that people in hospital
246 had poor health conditions. The results of subgroup analysis and meta-regression showed that studies
247 with high quality or larger sample size had smaller risk estimates. In multivariable meta-regression,
248 shorter sleep duration was linearly associated with higher prevalence of metabolic syndrome. Longer
249 sleep duration had no linear association. This “J-shaped” association was not consistent with the “U-
250 shaped” association between sleep duration reported in many articles²². However, we thought this
251 was not contradictory. In the meta-regression, “sleep duration” was a cut-off point defined by
252 different authors from different ethnicities; and in one specific study, the author calculated the
253 association among participants from a same ethnic.

254 Several mechanisms linked sleep duration to metabolic syndrome. Short sleep duration could lead to
255 the following endocrine changes, by affecting carbohydrate metabolism, hypothalamo-pituitary-
256 adrenal axis and sympathetic activity. Decreased glucose tolerance and insulin sensitivity would raise
257 the glucose levels; increased levels of ghrelin, decreased levels of leptin and increased appetite
258 correlated with higher waist circumference; increased cortisol concentrations were associated with
259 higher blood pressure^{23,24}. Short sleepers tended to have low-grade inflammation. Elevated levels of
260 high-sensitivity C-reactive protein and IL-6 correlated with cardiovascular events²⁵. Long sleep
261 duration was linked to sleep fragmentation, which would cause plenty of health outcomes, including
262 metabolic change²⁶. Long sleepers also have less time to take exercise, which might contribute to the
263 association²⁷. Both short and long sleep duration had bidirectional association with circadian rhythm,
264 which is a risk factor for metabolic disorders^{28,29}. Despite these mechanisms which could explain the
265 association, whether sleep duration was a causal risk factor for metabolic syndrome was still not
266 sure³⁰. Cohort studies still could not provide a causal result, though they have more power than cross-
267 sectional studies. To prove a causal relationship, we need further examine the effect of changes in
268 sleep duration³¹, and product Mendelian randomization study, a method using measured variation in
269 genes.

270 Our meta-analysis summarized the currently evidence of the association between abnormal sleep
271 duration and the risk of metabolic syndrome, and indicated that short sleep duration was a risk factor
272 for new onset metabolic syndrome. Strength of our study were the comprehensive search and strict
273 inclusion criteria. However, there were some limitations that should be taken into consideration. First,

274 the sleep categories varied between studies. There was no unified standard for definition of abnormal
275 sleep duration. Second, the estimates of relative risk had less accuracy than that in the individual
276 patient data meta-analysis. Third, we only included nine cohort studies, which prevent us from
277 conducting further research, such as subgroup analysis and meta-regression. Fourth, only two studies
278 used objective sleep measurement. More studies based on the objective measurement are needed in
279 the future.

280 **5 Conclusions**

281 Both short and long sleep duration was associated with high prevalence of metabolic syndrome cross-
282 sectionally. Short sleep duration, rather than long sleep duration, was associated with a significant
283 increase in risk for metabolic syndrome. Sufficient sleep duration should be recommended to prevent
284 metabolic syndrome.

285

286 **6 Author contributions**

287 Qi Fang and Jianian Hua contributed to the conception and design of the study. Jianian Hua
288 organized the database. Jianian Hua and Hezi Jiang performed the statistical analysis. Jianian Hua
289 wrote the first draft of the manuscript. Qi Fang and Hezi Jiang reviewed the manuscript. All authors
290 approved the final version of the paper.

291 **7 Funding**

292 This study was not supported by any funding.

293 **8 Conflicts of interest**

294 The authors declare that the research was conducted in the absence of any commercial or financial
295 relationships that could be construed as a potential conflict of interest.

296 **9 Preprint**

Author, Year	Study type (follow-up time)	Country, Continent	Sample size	Mean age ± SD, range	Male%	Study population	Sleep measurement	Metabolic syndrome measurement	Sleep (h)	Main findings reported in original articles: Adjusted HR/RR/OR (95% CI)
Choi, 2011 (male) ³²	Cohort (2-4)	Korea Asia	2093	40-55	0	Community	Interview	NECP ATP-III	<6 6-8 ≥10	aHR 1.80(1.06-3.05) Ref. aHR 1.57(0.61-4.01)
Choi, 2011 (female) ³²	Cohort (2-4)	Korea Asia	2133	40-55	100	Community	Interview	NECP ATP-III	<6 6-8 ≥10	aHR 0.62(0.24-1.64) Ref. aHR 1.66(0.71-3.88)
Otsuka, 2011 ³³	Cohort (3.7)	Japan Asia	2090	44.6 35-63	47.2	Community	Questionnaire	Japanese criteria	≤5 >6	aHR 3.18 (1.52-6.64) Ref.
Chaput, 2013 ³⁴	Cohort (6)	Canada North America	293	39.2±14.3 18-65	NA	Community	Questionnaire	AHA-NHLBI	≤6 7-8 ≥9	aHR 1.82(1.16-4.79) Ref. aHR 1.13(0.58-1.98)
Kim, 2015 ³⁵	Cohort (2.6)	Korea Asia	2579	54.1±8.3 ≥20	34.5	Company office	or Interview	AHA-NHLBI	<6 7-8 ≥10	aOR 1.41(1.06-1.88) Ref. aOR 0.68 (0.39-1.17)
Li, 2015 (male) ³⁶	Cohort (4.4)	China Asia	4774 for all	30-65	100	Community	Questionnaire	AHA-NHLBI	<6 7-8 >8	aRR 1.87 (1.51-2.30) Ref. aRR 1.96 (1.35-2.85)
Li, 2015 (female) ³⁶	Cohort (4.4)	China Asia	4774 for all	30-65	0	Community	Questionnaire	AHA-NHLBI	<6 7-8 >8	aRR 0.93 (0.73-1.19) Ref. aRR 0.93 (0.60-1.53)
Song, 2016 ³⁷	Cohort (2)	China Asia	11661	47.0±12.0 18-98	82.1	Hospital	Questionnaire	AHA-NHLBI	≤5.5 7 ≥8.5	aHR 1.22 (1.00-1.49) Ref. aHR 1.24 (0.93-1.66)
Deng, 2017 ¹²	Cohort (8)	Taiwan Asia	162121	20-80	47.4	Community	Questionnaire	AHA-NHLBI	<6 6-8 >8	aHR 1.09 (1.05-1.13) Ref. aHR 0.93 (0.88-0.99)
Itani, 2017 ³⁸	Cohort (7)	Japan Asia	39182	42.4±9.8 ≥20	100	Company office	or Questionnaire	Japanese criteria	<5 ≥5	aHR 1.08 (1.03-1.14) Ref.
Yingnan, 2020 ³⁹	Cohort (3)	China Asia	8969	56.7±7.7 35-75	35	Community	Questionnaire	Chinese Criteria	<6 7-8 >9	aOR 1.25(0.75 2.08) Ref. aOR 0.96 (0.69,1.33)

300 **10.2 Table 2. Subgroup meta-analysis of cross-sectional studies**

301

	Short sleep				Long sleep			
	No.	OR (95% CI)	I ²	P _z ^a	No.	OR (95% CI)	I ²	P _z
Gender								
Men	7	1.05 (0.98, 1.12)	46.0	Ref.	7	1.03 (0.99, 1.08)	14.0	Ref.
Women	7	0.99 (0.89, 1.09)	56.8	0.121	7	1.09 (1.00, 1.18)	67.9	0.272
		P=0.174 ^b				P=0.104		
Continent								
Asia	19	1.08 (1.01, 1.17)	75.8	Ref.	20	1.12 (1.05, 1.20)	79.0	Ref.
Europe	6	1.03 (0.98, 1.08)	20.8	0.271	6	1.17 (1.01, 1.36)	64.6	0.583
North Europe	5	1.31 (0.99, 1.74)	24.5	0.205	4	1.22 (0.75, 2.00)	15.0	0.736
South Europe	1	1.70 (1.19, 2.44)	0.0	0.016	1	1.08 (0.92, 4.26)	0.0	0.147
Africa	1	0.96 (0.51, 1.81)	0.0	0.708		P=0.171		
		P=0.173						
Study population								
Community	21	1.03 (0.98, 1.08)	57.7	Ref.	22	1.14 (1.07, 1.21)	65.9	Ref.
Hospital	5	1.36 (1.21, 1.53)	45.7	<0.001	5	1.10 (0.77, 1.59)	91.6	0.885
Company or office	6	1.15 (0.93, 1.41)	37.6	0.334	4	1.09 (0.93, 1.28)	0.0	0.644
		P<0.001				P=0.261		
Sleep measurement								
Questionnaire	16	1.08 (0.99, 1.18)	69.4	Ref.	15	1.11 (1.03, 1.20)	87.6	Ref.
Interview	8	1.13 (1.04, 1.23)	76.3	0.496	8	1.12 (1.01, 1.24)	36.6	0.893
Standard questionnaire	6	1.02 (0.92, 1.13)	0.0	0.363	6	1.13 (0.90, 1.40)	81.1	0.947
Objective	2	0.92 (0.67, 1.28)	0.0	0.349	2	1.27 (0.63, 2.56)	28.3	0.733
		P=0.012				P=0.021		
Definition of sleep duration								
< 5 for short or 9 for long	5	1.23 (0.98, 1.5)	29.2	Ref.	7	1.09 (0.92, 1.29)	67.3	Ref.
< 6 for short or for long	13	1.13 (1.02, 1.24)	82.4	0.492	17	1.18 (1.09, 1.27)	53.6	0.405
< 7 for short or for long	2	1.04 (0.98, 1.11)	20.4	0.164	6	1.01 (0.92, 1.11)	93.0	0.464
< 8	2	0.98 (0.90, 1.06)	0.0	0.065		P=0.121		
		P=0.154						
MetS measurement								
NECP ATP-III	12	1.06 (0.98, 1.16)	68.2	Ref.	10	1.07 (0.98, 1.15)	73.8	Ref.
Modified NECP ATP-III	6	1.00 (0.94, 1.07)	34.3	0.308	6	1.22 (1.15, 1.28)	35.8	0.006
AHA-NHLBI	9	1.20 (1.03, 1.39)	44.3	0.186	9	1.23 (1.01, 1.50)	27.3	0.195
IDF	3	1.05 (0.88, 1.25)	21.0	0.879	5	1.07 (1.01, 1.14)	33.4	0.945
Others	2	1.40 (1.22, 1.61)	14.1	<0.001	1	0.98 (0.81, 1.19)	10.1	0.426
		P<0.001				P<0.001		

302

303

304 Table 2-Continued Subgroup meta-analysis of cross-sectional studies\

305

	Short sleep				Long sleep			
	No.	OR (95% CI)	I ²	P _z	No.	OR (95% CI)	I ²	P _z
Sample size								
<5000	23	1.07 (0.99, 1.06)	49.7	Ref.	18	1.28 (1.12, 1.47)	56.2	Ref.
5000-20000	5	1.09 (0.96, 1.25)	57.4	0.842	8	1.05 (0.95, 1.15)	82.0	0.018
>20000	4	1.11 (1.00, 1.23)	51.3	0.638	5	1.09 (1.01, 1.18)	82.1	0.044
		P=0.004				P<0.001		
Study quality								
High	7	1.03 (1.00, 1.06)	26.9	Ref.	7	1.03 (0.97, 1.09)	60.5	Ref.
Low	25	1.06 (1.03, 1.09)	63.4	0.013	23	1.15 (1.06, 1.25)	70.7	0.030
		P=0.143				P<0.001		

306 ^aP value of two sample z-test for estimates between subgroups.

307 ^bP for heterogeneity.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332
333
334
335
336
337

338 **10.3 Table 3. Results of meta-regression analysis of cross-sectional studies**

339

	Short sleep duration			
	Univariable analysis		Multivariable analysis	
	Coef.	P value	Coef.	P value
Mean age, years	-0.01 (-0.02, -0.01)	0.020	-0.01 (-0.01, 0.00)	0.086
Proportion of males, %	0.08 (-0.10, 0.27)	0.356	-0.05 (-0.23, 0.14)	0.622
Definition of short/long sleep	-0.07 (-0.15, 0.01)	0.099	-0.08 (-0.15, -0.12)	0.011
Sample size	0.01 (-0.08, 0.09)	0.864	0.01 (-0.09, 0.09)	0.351
Study quality	-0.15 (-0.30, 0.00)	0.039	-0.26 (-0.61, 0.09)	0.149
	Long sleep duration			
	Univariable analysis		Multivariable analysis	
	Coef.	P value	Coef.	P value
Mean age, years	0.00 (0.00, 0.01)	0.113	0.00 (-0.00, 0.01)	0.720
Proportion of males, %	0.01 (-0.18, 0.02)	0.891	-0.04 (-0.44, 0.35)	0.828
Definition of short/long sleep	-0.16 (-0.33, 0.10)	0.776	-0.09 (-0.28, 0.10)	0.958
Sample size	-0.09 (-0.18, 0.00)	0.056	-0.08 (-0.25, 0.08)	0.318
Study quality	-0.01 (-0.14, 0.10)	0.807	0.01 (-0.50, 0.52)	0.360

340
341
342
343
344
345
346
347
348
349
350
351

352 **11 Figure legends**

353 **Figure 1.** Flowchart for the included studies.

354 **Figure 2. Forest plot of association between sleep duration and the risk of metabolic syndrome.**

355 (A) Comparing short sleepers with normal sleepers; (B) Comparing long sleepers with normal
356 sleepers.

357 **Figure 3. Forest plot of association between sleep duration and the prevalence of metabolic**

358 **syndrome.** (A) Comparing short sleepers with normal sleepers; (B) Comparing long sleepers with
359 normal sleepers.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388


389


390 12 References


- 391 1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the
392 metabolic syndrome. *Diabetes Care* 2001; **24**(4): 683-9.
- 393 2. Daly CA, Hildebrandt P, Bertrand M, et al. Adverse prognosis associated with the metabolic syndrome
394 in established coronary artery disease: data from the EUROPA trial. *Heart* 2007; **93**(11): 1406-11.
- 395 3. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United
396 States, 2003-2012. *JAMA* 2015; **313**(19): 1973-4.
- 397 4. Di Marzo V, Silvestri C. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.
398 *Nutrients* 2019; **11**(8).
- 399 5. Krittanawong C, Tunhasirwet A, Wang Z, et al. Association between short and long sleep durations
400 and cardiovascular outcomes: a systematic review and meta-analysis. *Eur Heart J Acute Cardiovasc Care*
401 2019; **8**(8): 762-70.
- 402 6. Jike M, Itani O, Watanabe N, Buysse DJ, Kaneita Y. Long sleep duration and health outcomes: A
403 systematic review, meta-analysis and meta-regression. *Sleep Med Rev* 2018; **39**: 25-36.
- 404 7. Ju SY, Choi WS. Sleep duration and metabolic syndrome in adult populations: a meta-analysis of
405 observational studies. *Nutr Diabetes* 2013; **3**: e65.
- 406 8. Iftikhar IH, Donley MA, Mindel J, Pleister A, Soriano S, Magalang UJ. Sleep Duration and Metabolic
407 Syndrome. An Updated Dose-Risk Metaanalysis. *Ann Am Thorac Soc* 2015; **12**(9): 1364-72.
- 408 9. Xi B. **Short sleep duration predicts risk of metabolic syndrome: A systematic review and meta-analysis.**
409 2014.
- 410 10. Karen Grace-Martin AG. Cohort and Case-Control Studies: Pro's and Con's. 2017;
411 <https://www.theanalysisfactor.com/cohort-and-case-control-studies-pros-and-cons/>.
- 412 11. Setia MS. Methodology Series Module 3: Cross-sectional Studies. *Indian J Dermatol* 2016; **61**(3): 261-
413 4.
- 414 12. Deng HB, Tam T, Zee BC, et al. Short Sleep Duration Increases Metabolic Impact in Healthy Adults: A
415 Population-Based Cohort Study. *Sleep* 2017; **40**(10).
- 416 13. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of
417 research findings. *BMJ* 2014; **348**: f7450.
- 418 14. Adenekan B, Pandey A, McKenzie S, Zizi F, Casimir GJ, Jean-Louis G. Sleep in America: role of
419 racial/ethnic differences. *Sleep Med Rev* 2013; **17**(4): 255-62.
- 420 15. Wells G SB, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for
421 assessing the quality of nonrandomised studies in meta-analyses. 2014;
422 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 423 16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*
424 2003; **327**(7414): 557-60.
- 425 17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
426 graphical test. *BMJ* 1997; **315**(7109): 629-34.
- 427 18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.


- 428 *Biometrics* 1994; **50**(4): 1088-101.
- 429 19. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
430 publication bias in meta-analysis. *Biometrics* 2000; **56**(2): 455-63.
- 431 20. W. V. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010; **2010**; **36**: 1-48.
- 432 21. Zhang Tiansong ZS. How to compare summary estimates of different subgroups in meta-analysis.
433 *Chinese Journal of Evidence-Based Medicine* 2017;
434 <https://www.ixueshu.com/document/be6c862ae782c141182f500f64e4272a318947a18e7f9386.html>.
- 435 22. Smiley A, King D, Bidulescu A. The Association between Sleep Duration and Metabolic Syndrome:
436 The NHANES 2013/2014. *Nutrients* 2019; **11**(11).
- 437 23. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function.
438 *Lancet* 1999; **354**(9188): 1435-9.
- 439 24. Zimberg IZ, Damaso A, Del Re M, et al. Short sleep duration and obesity: mechanisms and future
440 perspectives. *Cell Biochem Funct* 2012; **30**(6): 524-9.
- 441 25. Meier-Ewert HK, Ridker Pm Fau - Rifai N, Rifai N Fau - Regan MM, et al. Effect of sleep loss on C-
442 reactive protein, an inflammatory marker of cardiovascular risk. 2004
443 ; (0735-1097 (Print)).
- 444 26. Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality
445 relationship. *Sleep Med Rev* 2007; **11**(5): 341-60.
- 446 27. Stranges S, Dorn JM, Shipley MJ, et al. Correlates of short and long sleep duration: a cross-cultural
447 comparison between the United Kingdom and the United States: the Whitehall II Study and the Western New
448 York Health Study. *Am J Epidemiol* 2008; **168**(12): 1353-64.
- 449 28. Allebrandt KV, Teder-Laving M, Akyol M, et al. CLOCK gene variants associate with sleep duration in
450 two independent populations. *Biol Psychiatry* 2010; **67**(11): 1040-7.
- 451 29. Lemmer B, Oster H. The Role of Circadian Rhythms in the Hypertension of Diabetes Mellitus and the
452 Metabolic Syndrome. *Curr Hypertens Rep* 2018; **20**(5): 43.
- 453 30. Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS, Kupfer DJ. Coming to terms with the
454 terms of risk. *Arch Gen Psychiatry* 1997; **54**(4): 337-43.
- 455 31. Buysse DJ. Sleep health: can we define it? Does it matter? *Sleep* 2014; **37**(1): 9-17.
- 456 32. Choi JK, Kim MY, Kim JK, et al. Association between short sleep duration and high incidence of
457 metabolic syndrome in midlife women. *Tohoku J Exp Med* 2011; **225**(3): 187-93.
- 458 33. Otsuka T, Kawada T, Yanai M, Kitagawa Y, Kan H. [Incidence of metabolic syndrome and associated
459 lifestyle factors in a worksite male population]. *Sangyo Eiseigaku Zasshi* 2011; **53**(3): 78-86.
- 460 34. Chaput JP, McNeil J, Despres JP, Bouchard C, Tremblay A. Short sleep duration as a risk factor for
461 the development of the metabolic syndrome in adults. *Prev Med* 2013; **57**(6): 872-7.
- 462 35. Kim JY, Yadav D, Ahn SV, et al. A prospective study of total sleep duration and incident metabolic
463 syndrome: the ARIRANG study. *Sleep Med* 2015; **16**(12): 1511-5.
- 464 36. Li X, Lin L, Lv L, et al. U-shaped relationships between sleep duration and metabolic syndrome and
465 metabolic syndrome components in males: a prospective cohort study. *Sleep Med* 2015; **16**(8): 949-54.

- 466 37. Song Q, Liu X, Zhou W, Wang X, Wu S. Changes in sleep duration and risk of metabolic syndrome:
467 the Kailuan prospective study. *Sci Rep* 2016; **6**: 36861.
- 468 38. Itani O, Kaneita Y, Tokiya M, et al. Short sleep duration, shift work, and actual days taken off work are
469 predictive life-style risk factors for new-onset metabolic syndrome: a seven-year cohort study of 40,000 male
470 workers. *Sleep Med* 2017; **39**: 87-94.
- 471 39. Ye Y, Zhang L, Wang A, et al. Association of sleep duration with stroke, myocardial infarction, and
472 tumors in a Chinese population with metabolic syndrome: a retrospective study. *Lipids Health Dis* 2020; **19**(1):
473 155.
- 474










NOTE: Weights are from random effects analysis



NOTE: Weights are from random effects analysis